Product Description
ACP-044 is a novel, first-in-class, orally administered, non-opioid analgesic.
Mechanisms of Action: Free Radical Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Acadia
Company Location: Western America
Company CEO: Stephen R. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bunion|Acute Pain|Pain, Postoperative|Osteoarthritis, Knee
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05008835 |
ACP-044-005 | P2 |
Terminated |
Osteoarthritis, Knee |
2022-10-06 |
50% |
2025-01-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT04855240 |
Bunionectomy | P2 |
Completed |
Acute Pain|Bunion|Pain, Postoperative |
2022-02-11 |
48% |
2022-05-07 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/08/2022 |
News Article |
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results |
|
04/18/2022 |
News Article |
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain |
|
02/28/2022 |
News Article |
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results |
|
11/08/2021 |
News Article |
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results |